Literature DB >> 30472747

Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease.

Sandra M Holley1, Laurie Galvan1, Talia Kamdjou1, Carlos Cepeda1, Michael S Levine1.   

Abstract

The pathological hallmark of Huntington's disease (HD) is the massive loss of striatal and cortical neurons. Until recently, it was believed that striatal interneurons were spared from degeneration. This view has changed after the demonstration that parvalbumin (PV)-expressing interneurons also are vulnerable in humans. Here we compared morphological and functional changes of striatal fast-spiking interneurons (FSIs) and low-threshold spiking (LTS) interneurons in the Q175 mouse model of HD at presymptomatic (2 months) and symptomatic (12 months) stages of the disease. Electrophysiological intrinsic and synaptic properties of FSIs were significantly altered in symptomatic mice compared to wild-type (WT) littermates. Overall, FSIs became more excitable with disease progression. Sholl analysis also revealed a significant loss of dendritic complexity and excitatory synaptic inputs. The basic membrane and synaptic properties of LTS interneurons were similar in Q175 and WT mice regardless of disease stage. The resilience of LTS interneurons could be related to their sparsity of excitatory synaptic inputs compared with FSIs. However, in symptomatic mice, a subpopulation of LTS interneurons displayed an increase in action potential firing within oscillating bursts. Thus, we conclude that while both FSI and LTS interneurons demonstrate increases in excitability, the HD mutation differentially affects their membrane and synaptic properties as well as their ability to respond to compensatory challenges presented during the late stage of the disease. Alterations in GABAergic interneuron intrinsic activity and responsiveness to incoming signals may significantly affect SPN output thus contributing to abnormal motor movements in patients afflicted with HD.
© 2018 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  GABA interneurons; HD; electrophysiology; striatum

Mesh:

Year:  2018        PMID: 30472747      PMCID: PMC8320683          DOI: 10.1111/ejn.14283

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  68 in total

1.  Selective inhibition of striatal fast-spiking interneurons causes dyskinesias.

Authors:  Aryn H Gittis; Daniel K Leventhal; Benjamin A Fensterheim; Jeffrey R Pettibone; Joshua D Berke; Anatol C Kreitzer
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

2.  Selective sparing of a class of striatal neurons in Huntington's disease.

Authors:  R J Ferrante; N W Kowall; M F Beal; E P Richardson; E D Bird; J B Martin
Journal:  Science       Date:  1985-11-01       Impact factor: 47.728

3.  Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes.

Authors:  P E Marshall; D M Landis
Journal:  Brain Res       Date:  1985-03-11       Impact factor: 3.252

4.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.

Authors:  M Turmaine; A Raza; A Mahal; L Mangiarini; G P Bates; S W Davies
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

5.  Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.

Authors:  Tim Indersmitten; Conny H Tran; Carlos Cepeda; Michael S Levine
Journal:  J Neurophysiol       Date:  2015-02-11       Impact factor: 2.714

6.  Cortical interneuron loss and symptom heterogeneity in Huntington disease.

Authors:  Eric H Kim; Doris C V Thu; Lynette J Tippett; Dorothy E Oorschot; Virginia M Hogg; Richard Roxburgh; Beth J Synek; Henry J Waldvogel; Richard L M Faull
Journal:  Ann Neurol       Date:  2014-05-13       Impact factor: 10.422

7.  Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.

Authors:  D Dawbarn; M E De Quidt; P C Emson
Journal:  Brain Res       Date:  1985-08-12       Impact factor: 3.252

8.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

9.  Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition.

Authors:  D J Laurie; P H Seeburg
Journal:  Eur J Pharmacol       Date:  1994-08-16       Impact factor: 4.432

10.  Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia.

Authors:  Anton Reiner; Evan Shelby; Hongbing Wang; Zena Demarch; Yunping Deng; Natalie Hart Guley; Virginia Hogg; Richard Roxburgh; Lynette J Tippett; Henry J Waldvogel; Richard L M Faull
Journal:  Mov Disord       Date:  2013-09-03       Impact factor: 10.338

View more
  9 in total

1.  Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models.

Authors:  Carlos Cepeda; Michael S Levine
Journal:  Neuroscientist       Date:  2020-11-16       Impact factor: 7.235

2.  Striosomes Mediate Value-Based Learning Vulnerable in Age and a Huntington's Disease Model.

Authors:  Alexander Friedman; Emily Hueske; Sabrina M Drammis; Sebastian E Toro Arana; Erik D Nelson; Cody W Carter; Sebastien Delcasso; Raimundo X Rodriguez; Hope Lutwak; Kaden S DiMarco; Qingyang Zhang; Lara I Rakocevic; Dan Hu; Joshua K Xiong; Jiajia Zhao; Leif G Gibb; Tomoko Yoshida; Cody A Siciliano; Thomas J Diefenbach; Charu Ramakrishnan; Karl Deisseroth; Ann M Graybiel
Journal:  Cell       Date:  2020-10-27       Impact factor: 41.582

3.  Dysregulation of the Basal Ganglia Indirect Pathway in Early Symptomatic Q175 Huntington's Disease Mice.

Authors:  Joshua W Callahan; David L Wokosin; Mark D Bevan
Journal:  J Neurosci       Date:  2022-01-20       Impact factor: 6.709

4.  Enhanced GABAergic Inhibition of Cholinergic Interneurons in the zQ175+/- Mouse Model of Huntington's Disease.

Authors:  Sean Austin O Lim; D James Surmeier
Journal:  Front Syst Neurosci       Date:  2021-01-20

Review 5.  The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders.

Authors:  You-Hyang Song; Jiwon Yoon; Seung-Hee Lee
Journal:  Exp Mol Med       Date:  2021-03-19       Impact factor: 8.718

6.  BACHD Mice Recapitulate the Striatal Parvalbuminergic Interneuron Loss Found in Huntington's Disease.

Authors:  Vyshnavi Rallapalle; Annesha C King; Michelle Gray
Journal:  Front Neuroanat       Date:  2021-05-24       Impact factor: 3.856

7.  Translatome profiling in fatal familial insomnia implicates TOR signaling in somatostatin neurons.

Authors:  Susanne Bauer; Lars Dittrich; Lech Kaczmarczyk; Melvin Schleif; Rui Benfeitas; Walker S Jackson
Journal:  Life Sci Alliance       Date:  2022-10-03

8.  Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice.

Authors:  Yunping Deng; Hongbing Wang; Marion Joni; Radhika Sekhri; Anton Reiner
Journal:  J Comp Neurol       Date:  2020-09-20       Impact factor: 3.215

9.  Age-Dependent Degradation of Locomotion Encoding in Huntington's Disease R6/2 Model Mice.

Authors:  Hagar G Yamin; Noa Menkes-Caspi; Edward A Stern; Dana Cohen
Journal:  J Huntingtons Dis       Date:  2021
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.